Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
      Google Scholar   
Citation:
ESMO Open vol 9 (11) 103938
Year:
2024
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA232760; UG1CA233180, UG1CA233196, UG1CA233329, UG1CA233337, U10CA180820 (ECOG-ACRIN); U10CA180863 (Canadian Clinical Trials Group) and grant 704970 from the Canadian Cancer Society; U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                                                                                     
Networks:
AL068, LAPS-CT018, LAPS-MA036, LAPS-MD017, LAPS-MN026, SC019   
Study
NCCTG-N063D
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: